Context Therapeutics (CNTX) Depreciation & Amortization (CF) (2022 - 2026)
Context Therapeutics (CNTX) posted Depreciation & Amortization (CF) of $4687.0 for Q1 2026, up 15.3% sequentially from $4065.0 in Q4 2025, and up 15.59% YoY from $4055.0 in Q1 2025.
Context Therapeutics (CNTX) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Context Therapeutics has reported Depreciation & Amortization (CF) for 5 years, with the latest figure at $4687.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 15.59% year-over-year to $4687.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16883.0 (up 36.51% YoY) and the FY2025 annual result came in at $16251.0, up 49.35% from the prior year.
- Depreciation & Amortization (CF) rose to $4687.0 in Q1 2026 per CNTX's latest filing, from $4065.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $4687.0 in Q1 2026 and troughed at $2568.0 in Q4 2023.
- A 5-year average of $3320.7 and a median of $3193.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) dropped 19.6% in 2023, then jumped 58.29% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $3194.0 in 2022, then dropped by 19.6% to $2568.0 in 2023, then rose by 14.25% to $2934.0 in 2024, then soared by 38.55% to $4065.0 in 2025, then rose by 15.3% to $4687.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $4687.0, $4065.0, and $4066.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | 6,647.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6,647.00 |
| Jun 30, 2026 | 6,647.00 |
| Mar 31, 2026 | 4,687.00 |
| Mar 31, 2026 | 4,687.00 |
| Dec 31, 2025 | 4,065.00 |
| Dec 31, 2025 | 4,065.00 |
| Sep 30, 2025 | 4,066.00 |
| Sep 30, 2025 | 4,066.00 |
| Jun 30, 2025 | 4,065.00 |
| Jun 30, 2025 | 4,065.00 |
| Mar 31, 2025 | 4,055.00 |
| Mar 31, 2025 | 4,055.00 |
| Dec 31, 2024 | 2,934.00 |
| Dec 31, 2024 | 2,934.00 |
| Sep 30, 2024 | 2,811.00 |
| Sep 30, 2024 | 2,811.00 |
| Jun 30, 2024 | 2,568.00 |
| Jun 30, 2024 | 2,568.00 |
| Mar 31, 2024 | 2,568.00 |
| Mar 31, 2024 | 2,568.00 |